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BRIEF REPORT
The Management of Keloids: Hands-On Versus
Hands-Off
James Studdiford, MD, Amber Stonehouse, MD, Marc Altshuler, MD, and
Elliot Rinzler, MD
Keloids are benign fibrous growths that appear in scar tissue. The lesions can be severely disfiguring
and early recognition of genetic lesions is crucial. This case report outlines and reviews the important
management strategies for these lesions and the requirement for extensive counseling for the patient
and their family. Many potential medical and surgical interventions exist. Unfortunately, these lesions
tend to recur and overall outcomes remain poor. Given patient susceptibility to disfiguring results, sur-
gical intervention should be used with extreme caution. (J Am Board Fam Med 2008;21:149–152.)
Case Presentation
A 36-year-old African-American man was seen by
his family physician for management of morbid
obesity and hypertension. Although he was other-
wise healthy, he was noted to have marked keloid
formation along his jawline and occiput (Figure 1).
On further questioning he revealed that he had
keloid formation at a very early age; these lesions
formed over areas of bony prominence along his
shoulder, back, chest, occiput, and ear. These facial
lesions remained relatively stable until he began
shaving at age 12. At that time he described the
development of “shaving bumps,” or pseudofollicu-
litis barbae, which caused ongoing inﬂammation
and added to the keloid formation along his jawline
and neck. There was also signiﬁcant progression in
the bulk of the overall keloid covering his ears.
Surgical excision of the keloid tissue along both
ears was attempted at age 14, but this debulking
procedure exacerbated the problem. This surgical
procedure was not preformed at our institution,
and the operative and pathology reports were un-
available. Soon after the surgery, keloid formation
recurred to an even greater degree. At age 18, the
patient experienced the formation of new keloids
along his occiput and posterior skull (Figure 2). He
attributed this phenomenon to trauma associated
with participation in high school football competi-
tions. Two years ago, surgical removal of the ke-
loids along his face was again attempted. This time
prophylactic radiation therapy was initiated after
surgery in an attempt to inhibit ﬁbroblast prolifer-
ation and diminish the chance of keloid regrowth.
The repeated attempt at debulking was again un-
successful, and the keloids along his jawline, neck,
and ear returned at greater mass. He also revealed
a strong family history of keloids, with similar
spontaneous formation in several members of his
family. A pedigree (Figure 3) illustrates the preva-
lence and location of keloids in known relatives.
Given this patient’s strong family history, he and
his family members have since received extensive
counseling regarding the risk of future skin trauma,
avoidance of elective surgeries, early recognition of
infection, and genetic counseling if they are to have
children. With the impressive genogram and na-
ture of inheritance in his family, this patient prob-
ably has an autosomal dominant trait that would be
passed on to his children.
From a psychosocial point of view, the patient
admitted to embarrassment and low self-esteem
caused by the disﬁguring nature of his keloids. He
also reported being the subject of repeated ridicule
as a child that left him suffering from depression
and anxiety. After extensive counseling from his
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family doctor he became more comfortable with his
appearance, entered a supportive relationship, and
became gainfully employed.
Discussion
Keloids develop from a hyperproliferation of der-
mal ﬁbroblasts and uncontrolled collagen deposi-
tion driven by transforming growth factor (TGF)-
.1 These benign ﬁbrous growths represent
exuberant scar tissue that extends beyond the con-
ﬁnes of the initial trauma. These lesions tend to
recur after surgical excision and proliferate in a
pseudotumor manner. Keloids are distinguished
from hypertrophic scars, which adhere to the bor-
der of the original trauma and generally retain their
organized conﬁguration. Although the precise
pathogenesis is not fully understood, keloids have a
well-documented familial predilection, most com-
monly seen in Asian and African-American popu-
lations.2 They have been associated genetically
with HLA-B14, HLA-B21, HLA-Bw16, HLA-
Bw35, HLA-DR5, HLA-DQw3, and blood group
A.3 In a review by Marneros et al,4 a study of 14
pedigrees with familial keloids, the observed inher-
itance appeared to be autosomal dominant with
incomplete penetrance. Sporadic appearance of ke-
loids does exist, but distinct characteristics between
genetic and nongenetic keloids have not been de-
termined. Alterations of apoptosis, cell prolifera-
Figure 1. Large bulky keloid formation along the
jawline encompassing the ear and extending to the
occiput. Seen here after attempted surgical excision
with postoperative radiation therapy.
Figure 2. Multiple keloids along the occiput and
posterior skull as a result of trauma incurred while
wearing a football helmet worn during competitions.
Figure 3. Familial inheritance pattern of keloids.
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tion, and overactivation of insulin-like growth fac-
tor have all been implicated in the pathogenesis of
keloids.5,6 Sayah et al5 compared the expression of
64 apoptosis-related genes in keloids and normal
scars. Underexpression of 8 of these genes was
found in the ﬁbroblasts derived from keloid tissue.
Keloid ﬁbroblasts fail to undergo physiologically
programmed cell death and therefore continue to
produce connective tissue beyond the period ex-
pected for normal scars.
Diagnosis is based on the clinical appearance
and location of the scar tissue. Keloids may occur in
any location, particularly after trauma, but are seen
most commonly on the ears and over bony prom-
inences subject to repeated pressure and friction,
such as the sternum and mandible. Although gen-
erally asymptomatic, some keloids may be pruritic
or tender.
Given the generally poor response to treatment
of severe keloids, prevention should be the primary
strategy. (Strength of recommendation level C: ex-
pert opinion.)7 All patients at risk for keloid forma-
tion should be counseled to avoid unnecessary
trauma (for example, contact football in our pa-
tient), body modiﬁcation, and surgical interven-
tions, including tattoos, body piercing, and cos-
metic surgery. Any skin infections (such as
folliculitis, pseudofolliculitis, herpes zoster, acne,
or furuncles) in predisposed patients should be
treated aggressively to minimize inﬂammation.8
Young men need to be instructed in proper man-
agement of facial hair. Hair should be trimmed
with sharp scissors and cut no shorter than one-
eighth of an inch. The family physician should be
aware of other modes of prevention for patients
with a predisposition to keloid formation, such as
the use of semi-occlusive dressings for minor abra-
sions, splinting after surgical closure of an open
wound to avoid excessive tension on the skin, and
the use of pressure garments consisting of elasti-
cized material over wounds. Table 1 provides a
complete outline of prevention strategies for peo-
ple predisposed to keloid formation.
For painful or disﬁguring keloids, several treat-
ment options exist for minimizing bulk and recur-
rence (Table 1). A combination of these therapies is
most effective, but recurrences are common despite
therapy. The earlier keloids are treated, the more
likely it is that they will respond to therapy.
Intralesional steroids are the ﬁrst-line treatment
for most keloids: local anesthesia followed by tri-
amcinolone 5 to 40 mg/mL injected into the bulk
of the lesion. Injections can be repeated monthly,
but treatment should be discontinued if there is no
response after 4 injections. Skin atrophy and hy-
popigmentation may occur at higher doses. Seventy
percent of patients respond to intralesional corti-
costeroid injections with ﬂattening of keloids, al-
though the recurrence rate approaches 50% at 5
years.9
Scalpel, laser, or electro excision can be consid-
ered if injection therapy is unsuccessful. However,
these surgical treatments alone result in a recur-
rence rate of 45% to 100%.10 Therefore, excision
should be used in conjunction with preoperative,
intraoperative, and postoperative steroid injection
and prophylactic radiation therapy to achieve opti-
mum remission rate.
Cryosurgery alone, for keloids 6 mm in depth,
has been shown to reduce appearance of keloids in
up to 50% of patients.11,12 The major side effect is
permanent hypopigmentation, which limits use of
cryosurgery in patients with darker skin. Treat-
ment involves a 10- to 30-second freeze-thaw cycle
repeated up to 3 times per treatment session. Ther-
apy may be repeated once per month until response
occurs.
Table 1. Keloid Prevention and Treatment Strategies
Prevention strategies for use in people predisposed to
keloid formation
1. Pressure garment consisting of elasticized material over
wounds.
2. Moist healing by use of dressing impregnated with
ointment.
3. Semi-occlusive dressings for minor abrasions.
4. Splinting after surgical closure of an open wound to
avoid excessive tension on the skin.
5. Injection of triamciniolone acetonide.
6. Silicon gel dressing for 3 months.
Treatment options for patients with keloids*
1. Intralesional steroid injection
2. Surgical excision
a. Scalpel excision
b. Laser excision
c. Electro excision
3. Cryosurgery
4. 5-ﬂurouracil injection
5. Bleomycin injection
6. Interferon -2b injection
*Combination therapy, with one or more of the above treat-
ments, may have greater success rates.
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Several new therapies more speciﬁcally directed
at intervention and prevention of keloids have re-
cently been investigated. Lypka13 found that imi-
quimod, an immune-modulating medication, ef-
fects collagen synthesis in keloids. This study
reported that imiquimod signiﬁcantly suppressed
type I collagen expression in keloid ﬁbroblasts.13 In
another report, Berman et al11 describes the post-
operative use of topical imiquimod, which may fur-
ther reduce the recurrence of keloids. Although
more research needs to be done, these ﬁndings
suggest there may be immune-modulating medica-
tions available that could be used in conjunction
with surgery to decrease the recurrence of keloids.
Radiation therapy as the sole modality of treat-
ment must be used with caution given the long-
term risks of malignancy. This treatment should be
reserved for recalcitrant keloids that are resistant to
other therapies and are unable to be resected. Ad-
junctive radiation therapy is highly successful for
reducing keloid recurrence, particularly after sur-
gical excision, with reported control rates of 70%
to 90%.12
Conclusion
For patients with a history of keloids, special care
must be taken after traumatic skin injury. Physi-
cians should be aware that the skin should be closed
with minimal tension and the use of pressure dress-
ings for 3 to 6 months should be considered to
reduce keloid formation.14 Treatment options for
severe familial keloids, as outlined in this case, are
limited and often result in worsening keloid recur-
rence. The mainstay of therapy should be identiﬁ-
cation of at-risk individuals and extensive counsel-
ing regarding prevention. If need be, a combination
of therapies should be used to maximize success
rates. Surgical intervention should be used with
extreme caution given patient susceptibility to dis-
ﬁguring outcomes.
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